Action filgrastim in patients with significantly reduced amount is not known myeloid progenitor cells. Filgrastim increases the number of neutrophils by acting primarily on precursor cells of neutrophils.Therefore, in patients with a reduced content of progenitor cells (e.g., undergoing intensive chemotherapy or radiotherapy), the degree of increase neutrophil count may be lower.
There are reports of reaction “graft versus host” and fatalities in patients receiving masteron prop after allogeneic bone marrow transplantation.
When bone radiography revealed increase in dynamics of hematopoietic bone marrow activity in response to the therapy of human . These data should be taken into account when analyzing the results of bone radiography.
Precautions for patients undergoing mobilization
after bone marrow transplantation is conducted analysis of blood platelets and the amount of 3 times a week.
comparing the two recommended mobilization methods (filgrastim alone or in combination with myelosuppressive chemotherapy) for the same cohort of patients was conducted. The degree of difference between the results of laboratory determination of the number of masteron prop means that direct comparison between different studies is difficult. It is therefore difficult to recommend an optimum method.Selection of mobilization method should be carried out according to the common goals of patient therapy.
Previous treatment with cytotoxic agents
Patients who performed last active myelosuppressive therapy sufficient increase can not occur until the minimum recommended level or increasing the speed normalization platelet count.
Certain cytotoxic agents have specific toxicity towards hematopoietic progenitor cells and may adversely affect their mobilization. Prolonged use of such drugs as melfalin, carboplatin, carmustine or to mobilize progenitor cells may lead to a deterioration in the results. However, the simultaneous use of menfalana, karboplatna and carmustine with filgrastim effective in mobilizing. If you plan transplantation, it is recommended to plan their mobilization in the early stages of the course of treating a patient. Particular attention should be paid to the number of progenitor cells activated in such patients before the application of high-dose chemotherapy. If the mobilization could not get enough of the PBSC, you should consider alternative treatments that do not require the use of progenitor cells.
Estimating the number
Estimating the number mobilized in patients using the drug Tevagrastim should pay special attention to the method of quantitation. The results of flow cytometry analysis of masteron prop number differ depending on the method chosen, and therefore must be interpreted with caution results obtained in studies in different laboratories.
There is a complex but stable statistical relationship between the number entered in infusing and the recovery rate of platelet count after administration of high dose chemotherapy.
Minimum number equal to or greater than , resulting in the restoration of adequate hematological parameters and recommended on the basis of published data. Number , exceeding this value appears to be accompanied by a more rapid normalization, if the amount is less than the specified value cell recovery is slower blood parameters.
Precautions for healthy doporov in mobilization masteron prop
apheresis and cell mobilization procedures should be performed in centers with experience in this area.
PBSC Mobilization has direct clinical outcome when used in healthy donors and can be performed solely for the purpose allolgennoy stem cell transplantation.